UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OFDate ~~THE~~of ~~SECURITIES~~Report ~~EXCHANGE~~(Date ~~ACT~~of OFEarliest ~~1934~~Event Reported): December 11, 2012 (December 10, 2012)

Date of Report (Date of Earliest Event Reported): April 22, 2011 (April 18, 2011)

CHINA POLYPEPTIDE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware	333-151148	20-8731646
(State of Incorporation)	(Commission File No.)	(IRS Employer ID No.)

No. 11 Jiangda Road

Jianghan Economic Development Zone

Wuhan 430023

People’s Republic of China

(Address of Principal Executive Offices)

(86) 27 8351-8396

(Registrant’s Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

~~[ ]~~¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR.425)

~~[ ]~~¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~[ ]~~¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~[ ]~~¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1ITEM 4.01. CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT.

~~Item 4.01. Changes~~On inDecember ~~Registrant’s~~10, ~~Certifying~~2012, ~~Accountant~~our Board of Directors approved the dismissal of Marcum Bernstein & Pinchuk LLP (“MarcumBP”) as our independent registered public accounting firm, effective immediately.

OnMarcumBP ~~April~~was ~~18,~~appointed ~~2011,~~as ~~the~~our independent registered public accounting firm ofon ~~China~~April ~~Polypeptide Group~~22, ~~Inc.~~2011 (“and has not issued any audit opinions in relation to its services during the term ~~Company”),~~of its engagement. Bernstein & Pinchuk LLP (“~~B&P~~BP”), ~~informed~~was our independent registered public accounting firm prior to MarcumBP for the ~~Company~~period ~~that~~from February 5, 2010 through April 18, 2011. BP resigned as our independent registered public accounting firm as a result of B&P’s ~~entered~~entering into a joint venture agreement with Marcum LLP and formed ~~Marcum Bernstein & Pinchuk LLP (“~~MarcumBP”) in a transaction pursuant to which B&P merged its China operations into Marcum BP and certain of the professional staff of B&P joined MarcumBP as employees of MarcumBP. ~~and~~Pursuant ~~consequently B&P~~to ~~resigned~~a asletter ~~the~~issued ~~Company’s~~by ~~independent~~BP ~~registered~~dated ~~public~~April ~~accounting~~22, ~~firm~~2011, which was attached as Exhibit 16.1 Onto the Current Report on Form 8-K filed on April 22, 2011, ~~the~~BP ~~board~~confirmed ofthat ~~directors~~its ~~(the~~reports ~~“Board”)~~on of the Company’s ~~approved~~consolidated financial statements for the ~~appointment~~year ~~and~~ended ~~engagement~~September of30, as2010 ~~its~~did ~~independent~~not ~~registered~~contain ~~public~~an ~~accounting~~adverse ~~firm~~opinion ~~for~~or ~~the~~a ~~fiscal~~disclaimer ~~year~~of ~~ending~~opinion ~~September~~and 30were not qualified or modified as to uncertainty, ~~2011~~audit scope or accounting principles.

~~B&P’s~~During ~~reports on~~ the ~~Company’s~~period ~~consolidated~~from ~~financial~~April ~~statements for the year ended September 30~~22, ~~2010~~2011 ~~did not contain an adverse opinion or a disclaimer of opinion~~ and ~~were~~through ~~not qualified or modified as to uncertainty, audit scope or accounting principles. Since B&P’s engagement as~~ the ~~Company’s~~date ~~independent~~of this ~~registered~~Current ~~public~~Report ~~accounting firm~~ on ~~February~~Form 58-K, ~~2010 through April 18, 2011,~~ the ~~date~~Company ofhas ~~B&P’s~~had ~~resignation, there have been~~ no disagreements with MarcumBP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of ~~B&P~~MarcumBP, would have caused ~~B&P~~MarcumBP to make reference to the subject matter of ~~the~~such disagreements in its report ason ~~described~~the ~~in Item 304(a)(1)(iv) under Regulation S-K. There have also been no reportable events as provided in Item 304(a)(1)(v) under Regulation S-K since B&P~~Company’s ~~engagement~~financial statements ~~on February~~for 5,such ~~2010 through April 18, 2011~~period.

During the Company’s two most recent fiscal years ~~ended September 30, 2009~~ and ~~2010 and~~ through ~~April 22, 2011,~~ the date of ~~MarcumBP’s~~this ~~engagement,~~Current ~~neither~~Report ~~the Company, nor anyone~~ on ~~its~~Form ~~behalf~~8-K, ~~consulted~~there ~~with~~have ~~MarcumBP~~been ~~with~~no ~~respect~~reportable toevents (i) the application of accounting principles to a specified transaction, either completed or proposed; (ii) the type of audit opinion that might be rendered on the Company’s consolidated financial statements; or (iii) any matter that was either the subject of a disagreement as ~~described~~defined ~~in Item 304(a)(1)(iv)~~ under ~~Regulation S-K) or a reportable event as provided in~~ Item 304(a)(1)(v) ~~under~~ of Regulation S-K.

The Company provided ~~B&P~~MarcumBP with a copy of this Current Report on Form 8-K prior to its filing with the ~~foregoing~~U.S. ~~disclosure~~Securities and ~~requested~~Exchange ~~B&P~~Commission ~~furnish~~ (the ~~Company~~“SEC”) ~~with~~and requested that MarcumBP furnish a letter addressed to the ~~Securities~~SEC ~~and Exchange Commission~~ stating whether it agrees with the statements made ~~therein~~herein. AAttached ~~copy~~as ofExhibit ~~such~~16.1 ~~letter, dated April 22, 2011,~~ hereto is ~~filed~~a ascopy ~~Exhibit~~of ~~16.1~~MarcumBP’s letter to ~~this~~the ~~Current~~SEC ~~Report~~dated onDecember ~~Form~~11, ~~8-K~~2012.

~~ITEM~~Engagement ~~9.01.~~of ~~FINANCIAL~~New ~~STATEMENTS~~Independent ~~AND~~Registered ~~EXHIBITS.~~Public Accounting Firm

Concurrently with the decision to dismiss MarcumBP as our independent registered public accounting firm, the Board of Directors appointed on JPDH & Company (d“JPDH”) ~~Exhibits~~ December 10, 2012 as our independent registered public accounting firm.

Exhibit No.		Description
16.1		Letter to U.S. Securities and Exchange Commission from Bernstein & Pinchuk LLP

During the fiscal years ended September 30, 2011 and 2012 and through the date hereof, neither the Company nor anyone acting on its behalf consulted JPDH with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided to the Company or oral advice was provided that JPDH concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of a disagreement or reportable events set forth in Item 304(a)(1)(iv) and (v), respectively, of Regulation S-K.

2ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

~~SIGNATURE~~(d) Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit No.		Description

16.1		Letter to U.S. Securities and Exchange Commission from Marcum Bernstein & Pinchuk LLP

	China Polypeptide Group, Inc.
Date: April 22, 2011
	/s/ Dongliang Chen
	Name: Dongliang Chen
	Title: Chief Executive Officer

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	China Polypeptide Group, Inc.

Date: December 11, 2012

	/s/ Dongliang Chen
	Name: Dongliang Chen
	Title: Chief Executive Officer

Filing Compare · China Polypeptide Group, Inc.